Navigation Links
UV Flu Technologies to Commence a National TV Advertising Campaign
Date:5/16/2012

CENTERVILLE, Mass., May 16, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a television joint venture agreement with Stardust  International TV, of San Bernardino Ca., for the filming of a 60 second commercial, along with a 10 minute, "mini-infomercial." The commercial will run locally, regionally, and nationally, on a variety of television networks, including Comcast and Direct TV. The commercials will be run several hundred times to a potential audience of over 40 million households, while the mini-infomercial will run 4 times weekly to a variety of television stations.

"We think this is an outstanding opportunity to create brand awareness and sales for UV Flu," said Jack Lennon, President of UV Flu Technology. "Our FDA cleared device utilizes patented  break thru technology that eliminates the issues of maintenance and efficacy present in almost all but the most costly filter systems. The Viratech UV-400 patented technology kills airborne bacteria, reduces odors, volatile organic compounds, and a host of other airborne contaminants. Indoor Air Pollution has been shown to have direct links to sleep disorders, respiratory issues including asthma and allergies, cancer, diabetes and even the risk of stroke."

"Finally having a national TV commercial, that can educate the American consumer about the health benefits of using our device and breathing contaminant-free air indoors, we think will dramatically improve the awareness of our brand, and the importance of the whole space as well," said Mr. Lennon. "The recently announced launch of the Serta Ultimate Sleep System, which combines our Viratech air purifier, with one of Serta's finest memory foam mattresses, coupled with their local advertising and our new 60 second national commercial, should have a significant impact on long-term sales."

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's  ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.)  The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the worlds' finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.

For more information, visit: www.uvflutech.com. Or www.rxair.com

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD


UV Flu Technologies, Inc.
-----------------------------
John J. Lennon,  President & CEO

Investor Information:
Toll-Free: 1-877-358-5455
Web: www.uvflutech.com

 

 

 


'/>"/>
SOURCE UV Flu Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
4. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
5. Webb Telescope spinoff technologies already seen in some industries
6. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
7. ODT Forum Presents Regenerative Technologies
8. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
9. Life Technologies Showcases Leading Technologies for Cancer Research at the AACR Annual Meeting 2012
10. Cobalt Technologies Hits Key Commercial Milestone with Pretreatment Process Demonstration
11. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic Information for ... Discovery --> --> The ... sequence 100,000 individuals. It is intended to initially include populations ... North and East Asian countries. --> ... focus on creating phased reference genomes for all major Asian ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/10/2016)... 2016 Early-career researchers from ... , Uganda and Yemen ... and nutrition   Indonesia , Nepal ... and Yemen are being honored for their accomplishments ... also celebrated for mentoring young women scientists who are pursuing careers in ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):